Triple therapies plus different probiotics for Helicobacter pylori eradication

This prospective, open-label, pilot study aimed to evaluate the therapeutic role of either Lactobacillus reuteri ATCC 55730 (1 x 108 CFU, twice daily) or a multi-strain, high-dose probiotic (2 x 1010 CFU, twice daily) in addition to standard triple therapies for Helicobacter pylori eradication in 65 consecutive dyspeptic patients with H. pylori infection. Patients were assigned to either a standard 7-day triple therapy regimen, a standard 7-day triple therapy regimen + L. reuteri supplementation, a standard 7-day triple therapy regimen + multi-strain probiotic, or a 14-day triple therapy regimen + multi-strain probiotic. No regimen achieved >80% eradication rate. A 14-day therapy plus the multi-strain probiotic tended to achieve a higher eradication rate (71%) although there was no statistically significant differences in terms of eradication rates between the tested regimens (7-day: 62%; 7-day + L. reuteri: 53%; 7-day + multi-strain probiotic: 53%). Side-effects were lowest in the 7-day + L. reuteri group (6%), but there were no statistically significant differences between the groups (7-day: 27%; 7-day + multi-strain probiotic: 20%; 14-day + probiotic: multi-strain 33%).

Conclusion:

7–14 days triple therapy with or without probiotic supplementations failed to achieve acceptable H. pylori eradication rates.

Reference

Scaccianoce G, Zullo A, Hassan C, Gentili F, Cristofari F, Cardinale V, Gigliotti F, Piglionica D, Morini S. (2008) Triple therapies plus different probiotics for Helicobacter pylori eradication. Eur Rev Med Pharmacol Sci. 12:251-256.